A novel small molecule inhibitor of hepatitis C virus entry.

Small molecule inhibitors of hepatitis C virus (HCV) are being developed to complement or replace treatments with pegylated interferons and ribavirin, which have poor response rates and significant side effects. Resistance to these inhibitors emerges rapidly in the clinic, suggesting that successful...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Carl J Baldick, Michael J Wichroski, Annapurna Pendri, Ann W Walsh, Jie Fang, Charles E Mazzucco, Kevin A Pokornowski, Ronald E Rose, Betsy J Eggers, Mayla Hsu, Weixu Zhai, Guangzhi Zhai, Samuel W Gerritz, Michael A Poss, Nicholas A Meanwell, Mark I Cockett, Daniel J Tenney
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2010
Materias:
Acceso en línea:https://doaj.org/article/1ee8b0be7b894e5398d932dbcf2e4866
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!